Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole

Hormone Research

Volumn 62, Issue 3, 2004, Pages 113-118

  Riepe, Felix G ^a   Baus, Inka ^a   Wiest, Stephanie ^a   Krone, Nils ^a   Sippell, Wolfgang G ^a   Partsch, Carl Joachim ^a,b  

^a UNIVERSITY OF KIEL   (Germany)

^b Klin F Kinder und Jugendliche   (Germany)

Author keywords

Anastrozole; Gynecomastia, pubertal

Indexed keywords

ANASTROZOLE; ANDROSTENEDIONE; AROMATASE INHIBITOR; ESTRADIOL; GONADOTROPIN; PRASTERONE SULFATE; TESTOSTERONE;

ADOLESCENT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BREAST; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; GYNECOMASTIA; HUMAN; MALE; PRIORITY JOURNAL; PUBERTY; RISK ASSESSMENT; SCHOOL CHILD; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADOLESCENT; AROMATASE INHIBITORS; DEHYDROEPIANDROSTERONE SULFATE; ESTROGENS; GYNECOMASTIA; HUMANS; MALE; NITRILES; PILOT PROJECTS; PUBERTY; TREATMENT OUTCOME; TRIAZOLES;

EID: 4644304161     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079882     Document Type: Article

References (23)

1. Braunstein GD: Gynecomastia. N Engl J Med 1993;328:490-495.
2. Braunstein GD: Aromatase and gynecomastia. Endocr Relat Cancer 1999;6:315-324.
3. Lazala C, Saenger P: Pubertal gynecomastia. J Pediatr Endocrinol Metab 2002;15:553-560.
4. Wilson JD, Aiman J, Macdonald PC: The pathogenesis of gynecomastia. Adv Intern Med 1980;25:1-32.
5. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR, Bulun SE: Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15:342-355.
6. König R, Schönberger W, Neumann P, Benes P, Grimm W: Treatment of marked gynecomastia in puberty with tamoxifen. Klin Pädiatr 1987;199:389-391.
7. Parker LN, Gray DR, Lai MK, Levin ER: Treatment of gynecomastia with tamoxifen: A double-blind crossover study. Metabolism 1986;35:705-708.
8. Ting AC, Chow LW, Leung YF: Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg 2000;66:38-40.
9. Novoa FJ, Boronat M, Carrillo A, Tapia M, Diaz-Cremades J, Chirino R: Effects of tamoxifen on lipid profile and coagulation parameters in male patients with pubertal gynecomastia. Horm Res 2002;57:187-191.
10. Zachmann M, Eiholzer U, Muritano M, Werder EA, Manella B: Treatment of pubertal gynaecomastia with testolactone. Acta Endocrinol (Copenh) Suppl 1986;279:218-226.
11. Plourde PV, Dyroff M, Dukes M: Arimidex: A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994;30:103-111.
12. Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster A: ARIMIDEX: A new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 1995;53:175-179.
13. Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, Bryant M, Bulun SE: Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003;348:1855-1865.
14. von Schnakenburg K, Bidlingmaier F, Knorr D: 17-Hydroxyprogesterone, androstenedione, and testosterone in normal children and in prepubertal patients with congenital adrenal hyperplasia. Eur J Pediatr 1980;133:259-267.
15. Twesten W, Holterhus P, Sippell WG, Morlot M, Schumacher H, Schenk B, Hiort O: Clinical, endocrine, and molecular genetic findings in patients with 17beta-hydroxysteroid dehydrogenase deficiency. Horm Res 2000;53:26-31.
16. Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Stanford, Stanford University Press, 1959.
17. Rubin SD, Plourde PV, Reiter EO, Jou HC, Desrochers PE: A randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of anastrozole (ZD1033, ARIMIDEX) versus placebo for the treatment of gynecomastia in pubertal boys (abstract P1-664). 85th Annual Meeting of the Endocrine Society, Philadelphia, 2003.
18. Castiglione-Gertsch M: New aromatase inhibitors: More selectivity, less toxicity, unfortunately, the same activity. Eur J Cancer 1996;32:393-395.
19. Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L: A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: A randomised controlled trial. Lancet 2001;357:1743-1748.
20. Kletter GB, Padmanabhan V, Beitins IZ, Marshall JC, Kelch RP, Foster CM: Acute effects of estradiol infusion and naloxone on luteinizing hormone secretion in pubertal boys. J Clin Endocrinol Metab 1997;82:4010-4014.
21. Veldhuis JD, Rogol AD, Samojlik E, Ertel NH: Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man. J Clin Invest 1984;74:47-55.
22. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-2442.
23. Wickman S, Kajantie E, Dunkel L: Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab 2003;88:3785-3793.